Skip to main content
See every side of every news story
Published • loading... • Updated

Novo Says Wegovy Injection Lowers BMI and Obesity Rates in Children in Trial

The phase 3 trial found more than 40% of treated children no longer met obesity criteria after 68 weeks, with no growth or puberty safety concerns.

Summary by CNBC
Wegovy is already approved to treat obesity in children ages 12 and older, but there are currently no approved medications for those under 12.

10 Articles

BTBT
+2 Reposted by 2 other sources
Lean Right

Novo has studied the effect of semaglutide, found in the weight loss drug Wegovy, in children aged 6 to 12 years.

·Borås, Sweden
Read Full Article
Center

Novo has studied the effect of semaglutide, found in the weight loss drug Wegovy, in children aged 6 to 12 years.

·Copenhagen, Denmark
Read Full Article

Should children under 12 be treated with weight loss medication? Novo has found benefits from treatment with the weight loss medication Wegovy, while the World Health Organization (WHO) is concerned.

Health: The Vegovi drug showed high efficiency in the treatment of obesity in children between 6 and 11 years of age; almost 80 per cent of the participants in the clinical study have reduced the IMT by at least 10 per cent.

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 60% of the sources are Center
60% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

PR Newswire broke the news in Chicago, United States on Monday, November 16, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

News
Feed Dots Icon
For You
Search Icon
Search
Blindspot LogoBlindspotLocal